RxDoctor Payments Data

Laurence Conway, MD

Cardiovascular Disease · Medford, MANPI 1427011840

Payments from drug & device makers

$4,221in general payments, 2019–2025

Across 53 payments — averaging $79.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Boston Scientific$706
  • Shockwave Medical, Inc$464
  • AstraZeneca$241
  • Johnson & Johnson$144
  • Philips North America LLC$131
  • plus $435 from 9 others

What the payments were for

  • Travel & lodging$88221%
  • Food & beverage$3,33979%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,221 in reported general payments places this provider in the 60th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$615,033
Medicare patients
1,952
Services billed
7,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban429$600,126
FarxigaDapagliflozin Propanediol70$97,443
EntrestoSacubitril/Valsartan34$54,765
XareltoRivaroxaban34$47,137
JardianceEmpagliflozin21$35,323
Repatha SureclickEvolocumab45$34,730
Metoprolol Succinate671$14,304
Praluent PenAlirocumab15$13,066
Atorvastatin Calcium411$7,597
Amiodarone Hcl120$5,498
Torsemide99$4,341
Losartan Potassium233$2,600
ClopidogrelClopidogrel Bisulfate194$2,558
Diltiazem 24hr Er (Cd)Diltiazem Hcl61$2,461
Ranolazine ErRanolazine20$2,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$600,126429 claims
AstraZenecaFarxiga$241$97,44370 claims
NovartisEntresto$12$54,76534 claims
Johnson & JohnsonXarelto$144$47,13734 claims
Boehringer IngelheimJardiance$86$35,32321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Medford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →